Irish med tech firm Diaceutics has announced a five-year multi-million euro partnership with US-based BioReference Laboratories.
The partnership will see Diaceutics acquire real-time testing data from BioReference, allowing it to help pharmaceutical companies achieve faster rollouts of new drugs through a better understanding of the US diagnostics market.
“Diagnostic data from laboratories like BioReference helps pharmaceutical companies better understand the testing journey that patients go on in the often difficult search for a targeted therapy,” Peter Keeling, Diaceutics’s chief executive, said. “That information allows pharma to pinpoint patients that need to be on a specific – and often life-changing – drug, accelerate speed to market for new drugs and improve patient outcomes.”
It comes as United Drug announces a €40m investment in technology and innovation at its Dublin headquarters. The move will increase distribution by almost two-thirds, with plans for further expansion over the next three years.
Meanwhile, medtech investors and start-ups will gather in Dublin this week at the Medtech Strategist Innovation Summit at the Shelbourne. Hotel.
Article Source: http://tinyurl.com/kbwqb42